As new and advancing tools for automating the drug discovery process yield potential drug candidates at an accelerating rate, attention is focusing on the areas of drug formulation and preclinical development as critical steps in the path to commercializing new chemical entities and driving the financial success of drug companies. More than ever before, drug formulation technology is now seen as a key enabler of new prescription products. Much of the current focus in formulation science is concerned with processes that can improve the solubility of APIs. The importance of solubilization technologies is also underscored by the capability they bestow on formulators attempting to re-formulate approved drugs approaching the end of their patent life.
